Trending Topic

Breast Cancer
29 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Keiichi Fujiwara, ESMO 2022: Phase 3 GOTIC-002 LUFT study results – Chemotherapy with tegafur-uracil for locally advanced cervical cancer

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 12th 2022

Maintenance chemotherapy with oral tegafur-uracil (UFT) after surgery has been shown to prolong survival in lung, breast, gastric and colon cancer. Dr Keiichi Fujiwara (Saitama Medical University International Medical Centre, Saitama, Japan) joins touchONCOLOGY to discuss the phase 3 GOTIC-002 LUFT study results, investigating the efficacy of maintenance chemotherapy using UFT following concurrent chemoradiotherapy for locally advanced cervical cancer.

The abstract entitled ‘Randomized phase III trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial ‘ Abstract LBA31, was presented at European Society for Medical Oncology (ESMO) 2022.

Questions:

  1. What was known about the impact of maintenance chemotherapy with tegafur-uracil (UFT) after surgery on cancer survival? (0:43)
  2. What were the aims, design and eligibility criteria of the GOTIC-002 LUFT study? (1:58)
  3. What were the study findings in terms of efficacy, safety and tolerability? (2:57)
  4. Why do you think UFT failed to improve overall survival? (4:10)
  5. What other GOTIC studies are planned or ongoing? (5:27)

Disclosures: Keiichi Fujiwara receives grant/research support from Taiho; is on the advisory board for Daiichi Sankyo, Seagen, and Genmab; and receives honoraria/honorarium from Kiowa KIRIN.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of ESMO 2022

Access more gynaecological oncology here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup